Clinical trials
Idiopathic Membranous Nephropathy clinical trials
Below are recruiting idiopathic membranous nephropathy clinical trials, each written for real people, not researchers. We’re tracking 10 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04456816RecruitingPhase 2
Drug test for IgA? No—anti-PLA2R positive immune kidney disease
This Phase 2 trial studies AP1189 in people with a specific immune-related kidney disease called iMN and very high urine protein. It aims to see whether the drug is safe and tolerable and if it can reduce protein in the urine.
AarhusAges 18–85 - NCT04095156Recruiting
Study of immune B cells in membranous nephropathy
This study looks at immune “B cells” in people with membranous nephropathy (a kidney disease). It includes people who have received or are being considered for B-cell–depleting treatment, aiming to better understand what drives the disease and how it may respond.
Ranica, BGAges 18 years+ - NCT05839314RecruitingPhase 4
Huaier granules for idiopathic membranous nephropathy with PLA2R
This trial studies whether Huaier granules can improve kidney disease activity in people with “idiopathic membranous nephropathy” who test positive for PLA2R antibodies and are still not in remission. Participants will also have been on standard blood-pressure/kidney-protecting treatment (called RASI) for at least 4 weeks.
Beijing, Beijing MunicipalityAges 18–75 - NCT07404436RecruitingPhase 4
Blood thinner to prevent clots in kidney disease
This trial tests whether the blood thinner rivaroxaban can prevent dangerous blood clots in people with a kidney condition called membranous nephropathy who have low albumin levels and are at high risk for clots.
Beijing, Beijing MunicipalityAges 18–80 - NCT06982729RecruitingPhase 1
Testing YK012 for primary membranous nephropathy
This trial tests a new drug called YK012 for people with primary membranous nephropathy, a kidney disease where protein leaks into the urine. The goal is to see if this treatment can reduce protein loss and protect kidney function.
Beijing, Beijing MunicipalityAges 18–80 - NCT00977977RecruitingPhase 2
Rituximab plus cyclosporine for membranous kidney disease
This trial tests whether rituximab (an immune-targeting medicine) plus cyclosporine (another immune medicine) can better control protein leakage in the urine for people with idiopathic membranous nephropathy. It may help reduce long-lasting kidney damage risk when standard treatments like ACE inhibitor or ARB don’t control the protein level.
Bethesda, MarylandAges 18–90 - NCT04745728RecruitingPhase 3
Testing different immune-suppressing treatments for membranous kidney disease
This Phase 3 trial compares different immune-suppressing medicines for idiopathic membranous nephropathy (a kidney disease caused by the immune system). It may help reduce heavy protein leakage in the urine and improve disease control in people who fit specific prior-treatment and lab requirements.
Beijing, Beijing MunicipalityAges 18–80 - NCT07516964Recruiting
Studying autoimmune kidney disease in children and adults
This study collects medical information and samples from patients with podocytopathy—a type of autoimmune kidney disease that causes protein leakage into urine. Researchers will analyze your medical records and any blood or kidney tissue samples you've already had to better understand the disease and find better treatments.
Rochester, MinnesotaAges birth–99 years - NCT06760845Recruiting
Using light to diagnose kidney disease
This trial uses a special light technique (Raman spectroscopy) to help diagnose different types of kidney disease. It may provide a faster, less invasive way to understand your condition.
Jinan, ShandongAges Any age - NCT05505500Recruiting
Parent and patient interviews for childhood kidney swelling
This study uses interviews to understand how swelling from nephrotic syndrome affects daily life for children and their caregivers. It may help researchers design better care by capturing the patient and parent perspective.
Ann Arbor, MichiganAges 2 years+
Hear when a new Idiopathic Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for idiopathic membranous nephropathy?
- Yes. Clin2 currently lists 10 recruiting idiopathic membranous nephropathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a idiopathic membranous nephropathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a idiopathic membranous nephropathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.